"This analysis explores the critical shifts in the sector, highlighting a projected growth trajectory driven by technological integration and changing consumer dynamics."

According to analysts at Vantage Market Research, the United States Cell Therapy Manufacturing Market size is worth USD 4.82 Billion in 2025 and is projected to reach USD 18.67 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 14.5% from 2026 to 2035. Key trends include expansion of commercial cell therapy production, automated and closed-system manufacturing, increasing CDMO partnerships, allogeneic cell therapy platforms, modular manufacturing facilities, AI-enabled process analytics, digital quality management, and growing adoption of scalable manufacturing technologies.

United States Cell Therapy Manufacturing Market Overview

The United States Cell Therapy Manufacturing Market represents a strategically important segment of the biopharmaceutical manufacturing ecosystem, supported by the commercialization of personalized cellular therapies and continued development of next-generation treatments. Manufacturers are transitioning from laboratory and clinical-scale production toward commercially scalable environments designed to support regulatory compliance, consistent product quality, supply continuity, and increasingly complex therapy portfolios.

Growing demand for CAR-T therapies and other advanced cellular treatments is encouraging pharmaceutical and biotechnology companies to invest in dedicated manufacturing infrastructure, automated production systems, closed-system technologies, and integrated quality-management platforms. Procurement strategies are increasingly focused on manufacturing ecosystems that combine cell processing, genetic modification, expansion, formulation, cryopreservation, analytical testing, and digital monitoring capabilities.

The expansion of contract development and manufacturing organizations is also reshaping the U.S. manufacturing landscape. Biotechnology companies increasingly engage specialized CDMOs to access validated infrastructure, technical expertise, regulatory support, and scalable production capacity without committing to extensive internal capital investment. Decentralized and modular manufacturing models are also gaining attention as developers seek to shorten production timelines and improve coordination between manufacturing facilities and treatment centers. Catalent, for example, announced a collaboration with Galapagos in January 2025 to support decentralized manufacturing of an investigational CAR-T therapy through its New Jersey facility.

Automation is becoming a central technology priority across the industry. Closed and automated platforms can reduce manual intervention, improve process consistency, strengthen contamination control, and support standardized production across facilities. Cellares received FDA Advanced Manufacturing Technology designation for its Cell Shuttle platform in April 2025, highlighting the growing regulatory attention toward automated cell therapy manufacturing technologies.

The United States market is also evolving toward digitally connected manufacturing environments incorporating manufacturing execution systems, electronic batch records, real-time analytics, predictive maintenance, and integrated quality-management platforms. These developments are strengthening demand for manufacturing solutions that combine operational scalability with regulatory readiness and data interoperability.

Overall, the United States Cell Therapy Manufacturing Market is moving toward industrialized, automated, and digitally integrated production models as therapy commercialization expands and manufacturers prioritize scalable infrastructure, manufacturing consistency, and long-term supply reliability.

Cellares Expanded Automated Cell Therapy Manufacturing Capabilities Through Strategic Industry Developments

April 2026 — Cellares and Cabaletta Bio entered a 10-year commercial supply agreement for automated manufacturing of rese-cel, following first-patient dosing of the autologous CAR-T therapy manufactured using Cellares’ automated Cell Shuttle platform.

Key Takeaways from the Report

Expanding commercialization of CAR-T and other cellular therapies is accelerating investment in scalable U.S. manufacturing infrastructure.
Autologous cell therapy manufacturing remains the leading manufacturing model due to its established commercial presence and individualized production requirements.
Allogeneic cell therapy manufacturing is gaining momentum as developers pursue standardized, off-the-shelf therapies capable of supporting broader patient populations.
Commercial-scale manufacturing is becoming increasingly important as approved and late-stage therapies require reliable production capacity, standardized quality systems, and continuous operational capabilities.
Automated and closed-system manufacturing platforms are transforming production workflows by reducing manual intervention and improving reproducibility, contamination control, and operational consistency.
CDMO manufacturing is expanding as emerging biotechnology companies seek specialized infrastructure, regulatory expertise, analytical capabilities, and flexible production capacity.
AI-enabled manufacturing analytics, digital quality management, predictive maintenance, and connected manufacturing systems are creating new opportunities for technology providers.
Decentralized manufacturing models are supporting efforts to bring production capabilities closer to treatment centers and improve coordination across patient-specific workflows.
Regulatory readiness, process validation, data interoperability, cybersecurity, and lifecycle technical support are becoming increasingly important procurement criteria.
Strategic investment in modular manufacturing facilities and integrated automation platforms is expected to shape the U.S. cell therapy manufacturing landscape through 2035.

Top Players

Thermo Fisher Scientific Inc.
Lonza Group AG
Catalent, Inc.
Cytiva
Cellares
Miltenyi Biotec
Fujifilm Diosynth Biotechnologies
Bio-Techne Corporation
Charles River Laboratories
Sartorius AG
Danaher Corporation
RoslinCT
Minaris Regenerative Medicine
WuXi Advanced Therapies

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional and industry-specific market landscapes, and evaluate the impact of major events affecting healthcare and biopharmaceutical manufacturing. Additionally, our reports feature a detailed competitive landscape, including company profiles, strategic developments, manufacturing capabilities, and technology positioning, providing actionable intelligence to empower business strategies.

Latest Announcement

June 2026 — Cellares announced that it had joined the New American Industrial Alliance while highlighting its U.S.-based Smart Factory network in South San Francisco and Bridgewater. The company stated that its U.S. facilities are expected to support commercial cGMP operations beginning in 2027, with capacity designed to support up to 50,000 patient doses annually.